• Explore /
  • Poster
  • / NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

Abstract Poster

Authors

null

Lili Mao

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma Oncology, Peking University Cancer Hospital & Institute, Beijing, China

Lili Mao , Lu Si , Jie Dai , Xue Bai , Caili Li , Xiaoting Wei , Chuanliang Cui , Zhihong Chi , Xinan Sheng , Bixia Tang , Bin Lian , Xuan Wang , Xieqiao Yan , Li Zhou , Yan Kong , Xiaowen Wu , Siming Li , Juan Li , Jun Guo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT04622566

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9514)

DOI

10.1200/JCO.2023.41.16_suppl.9514

Abstract #

9514

Poster Bd #

277

Abstract Disclosures

Similar Posters

First Author: Richard Cathomas

Poster

2020 ASCO Virtual Scientific Program

A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.

A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.

First Author: Maria Gonzalez

First Author: Chiara Mercinelli

First Author: Lisanne P. Zijlker